Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Extending Genome-Phenome Analysis

    SBC: SimulConsult, Inc.            Topic: 172

    DESCRIPTION provided by applicant The declining cost of whole exome sequencing WES is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the results and comparing them to the patientandapos s clinical findings This project builds on our demonstrated capability to reduce this interpretation cost by pairing our diagnostic sof ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Emergency Operations Plans for Individuals with Disabilities

    SBC: Praxis            Topic: NICHD

    DESCRIPTION provided by applicant The proposed project is designed to fill an important yet unmet need by developing an online education program using simulations and scenario based learning to reach all public health and safety emergency responders and students responsible for emergency planning with and response for individuals with disabilities In Phase II the applicant organization P ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a clinical hemoglobin modulator

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The thalassemias and sickle cell disease are serious genetic blood diseases which are WHO designated as a growing global health burden The disorders decrease production or alter structure of the b chain of adult hemoglobin A and are characterized by anemia chronic organ damage and early mortality HbF is another type of normal hemoglobin which is suppres ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. High-Speed Three-Channel Photonic Time Delay Unit

    SBC: AGILTRON, INC.            Topic: MDA08T012

    An innovative, super-miniature, fast-switching array-based photonic time delay device is being developed for the active electronically scanned-array (AESA) MDA and Navy radars. The design is based on the fast electro-optic effect, the super miniature fiber-lens collimation array, and the existing WDM photonic true time delay technologies. In Phase I Agiltron has successfully demonstrated the core ...

    STTR Phase II 2011 Department of DefenseMissile Defense Agency
  8. Modeling Operator Reasoning and Performance for Human-in-Control Simulation (MORPHIC)

    SBC: Charles River Analytics, Inc.            Topic: MDA12T006

    Propose development of a human-in-control (HIC) modeling capability that can: (1) represent the breadth of operator decision-making processes across missile defense elements, (2) scale to deliver the appropriate level of fidelity, and (3) be extensible to future operator needs. To provide this HIC modeling capability, we propose to develop and evaluate a full-scope prototype of Modeling Operato ...

    STTR Phase II 2014 Department of DefenseMissile Defense Agency
  9. Stratospheric Electrical Environments Applicable To Photovoltaic Arrays On HAA Platforms

    SBC: LIGHTNING TECHNOLOGIES, INC.            Topic: MDA04T008

    The objective of this program is to characterize the upper atmosphere electrical environment so that the effects of this environment on high altitude airships (HAA) and other platforms intending to operate in this environment can be determined, and protection methods developed. This includes transient luminous events (TLEs), such as red sprites and blue jets and their associated electrical propert ...

    STTR Phase II 2005 Department of DefenseMissile Defense Agency
  10. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government